Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amiotide is a biochemical ophthalmic preparation derived from animal tissues, specifically pig thyroid and vitreous humor. It consists of a complex mixture of amino acids, organic iodine, and peptides. Developed and manufactured by Hangzhou Guoguang Pharmaceutical, it is primarily indicated for the prevention and treatment of early-stage senile cataracts and vitreous opacities. The drug functions by improving the local metabolism of the lens and vitreous body, enhancing ocular blood circulation, and providing essential nutrients to eye tissues. By promoting the absorption of opacities and maintaining lens transparency, it helps slow the progression of degenerative eye conditions. It is administered topically as eye drops.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amiotide.